The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | Addressing fears or misconceptions patients may have during the CAR-T process
Mairéad Ní Chonghaile, RGN, BNS, MSc, St James’s Hospital, Dublin, Ireland, discusses the role of the nurse in appropriately addressing fears or misconceptions patients may have before and during the CAR T-cell therapy process, noting that patients may often direct questions and concerns at nurses by their bedside. She highlights the role of education programs, including print materials and e-learning platforms, in equipping nurses with the necessary skills and knowledge to address patient concerns and provide supportive care, thereby enhancing long-term survivorship. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s becoming very interesting because very early on with an awful lot of patients up until recently as CAR-T is moving into second-line and first-line settings, even in some places, and the talk about doing that, the misconceptions have been very much that this is a last-ditch thing, so I think patients’ perceptions are changing. When CAR-T started a number of years ago, it was kind of a last-ditch, we were going to do anything, and patients didn’t not appreciate the risks, they appreciated them, but they didn’t, in a way, care about them because it was anything for survival...
It’s becoming very interesting because very early on with an awful lot of patients up until recently as CAR-T is moving into second-line and first-line settings, even in some places, and the talk about doing that, the misconceptions have been very much that this is a last-ditch thing, so I think patients’ perceptions are changing. When CAR-T started a number of years ago, it was kind of a last-ditch, we were going to do anything, and patients didn’t not appreciate the risks, they appreciated them, but they didn’t, in a way, care about them because it was anything for survival. I think it’s becoming much more different now because the risks are, you know, from a quality-of-life point of view, and what we’re going to do, and like one of the sessions we had yesterday was on survivorship and quality of life, that it’s not just long-term follow-up, that survivorship and living with, and living post these treatments is really important. And that may be sometimes the stressful element, and the anxiety element, and that you’re not leaving people post-traumatic stress, and nurses are really important in helping patients navigate that. They’re often, sometimes, at the bedside, and you’re the person that they’re going to discuss this about, you know, “I’ve been given this option”, and you need to have the knowledge to do that. So that’s where meetings like this, but also education programs, like we as HNHCP, as a group, have, where we have our CAR-T learning programs, our bispecific learning programs, but also other disease-specific ones, are really important, both from a printed material, but also the e-learning platform that we have, are really important to help nurses have those skills and the knowledge to be able to answer those questions.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
